- June 10, 2021
- Posted by: Bastion team
- Category: Featured
BRASILIA (REUTERS) – Brazil’s health regulator Anvisa on Wednesday (June 9) authorised phase one and two clinical tests to be carried out on volunteers for the Butanvac vaccine developed by Sao Paulo’s Butantan Institute biomedical centre.
The tests for the two-shot vaccine were initially authorised for 400 volunteers, but will later involve an expected total of 6,000 volunteers aged 18 and over, Anvisa said.
The vaccine developed by Butantan, one of Brazil’s two top biomedical research centres, will not need imported active ingredients like the main vaccines produced in Brazil, the AstraZeneca shot and Sinovac Biotech’s CoronaVac.
Sao Paulo state governor Joao Doria, celebrating the Anvisa authorisation on Twitter, said Butantan has seven million doses of Butanvac ready.
Recommended articles
- IFS completes the acquisition of global Enterprise Service Management provider Axios Systems
LONDON and EDINBURGH, Scotland, June 10, 2021 /PRNewswire/ -- IFS, the global cloud enterprise applications company, announces that it has concluded the acquisition of Axios Systems.The transaction, w...(read more)
- CleanEquity® Monaco 2021 – Registration and Collaboration
LONDON, June 10, 2021 /PRNewswire/ -- CleanEquity® was founded in 2007 by His Serene Highness Prince Albert II of Monaco & Mungo Park, Chair of Innovator Capital. The conference, aimed at accelerating...(read more)
- Three 'explosive-laden drones' used in Baghdad airport attack: Army
BAGHDAD (AFP) - The latest attack on Baghdad airport, where US soldiers are deployed, was carried out with three "explosive-laden drones", the army said in a statement Thursday (June 10). It said one...(read more)
- Potatoes for McDonald's fries are reportedly grown on Bill Gates' farmland in fields so vast that you can see them from space
Microsoft cofounder Bill Gates. Paul Richards/AFP via Getty Images
- Moderna Files For EUA For Its COVID-19 Vaccine In Adolescents In US – Quick Facts
(RTTNews) - Biotechnology company Moderna, Inc., (MRNA) announced Thursday that it has requested an emergency use authorization (EUA) for its COVID-19 vaccine in adolescents with the U.S. Food and Dru...(read more)
